The data thus far suggests that tamoxifen has a role in estrogen-receptor blockade and the prevention of a contralateral breast cancer, even among BRCA1 mutation carriers who have a tendency to develop this hormone-receptor negative disease. This evidence concerns the gene BRCA1 and breast cancer.